Journal
GYNECOLOGIC ONCOLOGY
Volume 96, Issue 3, Pages 902-905Publisher
ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.ygyno.2004.12.001
Keywords
bevacizumab; ovary; ovarian
Categories
Ask authors/readers for more resources
Background. Angiogenesis is pivotal in the development and progression of ovarian cancer and is an ideal candidate for novel treatment approaches. Case. A case of advanced, recurrent and refractory serous carcinoma is presented that responded to bevacizumab 15 mg/m(2) intravenously every 3 weeks after failing eleventh line cytotoxic chemotherapy and radiation. An objective durable response lasting at least 5 months was documented. Conclusion. Bevacizumab has activity in epitlielial ovarian carcinoma and larger scale trials are indicated. (c) 2004 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available